Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Recursion Pharmaceuticals, Inc. - Class A Common Stock (NQ:RXRX)

5.650 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 30, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Recursion Pharmaceuticals, Inc. - Class A Common Stock

< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Where Will Recursion Pharmaceuticals Be in 3 Years?
This biotech could still be a long way from having a drug on the market in 2026. 
Via The Motley Fool
2 Brilliant Growth Stocks With Upsides of About 70%, According to Wall Street
Wall Street analysts foresee these pre-commercial-stage drugmakers rocketing higher over the next 12 months. 
Via The Motley Fool
3 Biotech Stocks to Invest In for Big-Time, Long-Term Gains
These biotech stocks to buy and hold offer tremendous upside blending long-term potential with healthcare advances. 
Via InvestorPlace
Recursion to Participate in Upcoming Investor Conferences
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Announces Completion of Phase 1 Study for REC-3964 for Clostridioides Difficile Infection
REC-3964 has been well tolerated in healthy volunteers with no reported serious adverse events. Recursion to explore initiating a Phase 2 proof-of-concept study in patients with recurrent... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Analyst Expectations for Recursion Pharmaceuticals's Future
 
Via Benzinga
Cathie Wood Just Sold Nvidia -- and Bought These 5 Potentially Explosive Growth Stocks Again
The famous growth investor has been making some interesting stock moves lately. 
Via The Motley Fool
Better AI Biotech Stock: Recursion Pharmaceuticals vs. 23andMe
Both businesses have a lot to prove. 
Via The Motley Fool
Topics Artificial Intelligence
Cathie Wood's Ark Invest Adjusts Portfolio — Sells Nvidia Shares Worth Nearly $1.9M Amid AI Surge
 
Via Benzinga
Topics Artificial Intelligence
Cathie Wood Just Sold Shopify -- and Bought These 7 Potentially Explosive Growth Stocks
The Ark Invest CEO continues to trim Shopify holdings to fund some big purchases. 
Via The Motley Fool
3 Clever Tricks to Find Winning Biotech Stocks
You'll need to dig into company details, but the effort is worthwhile. 
Via The Motley Fool
AI Bubble Stocks Deflating, Down 14% So Far In August
13 artificial intelligence and related stocks have dramatically outpaced the sector in general since the AI&R bubble began to inflate at the end of April. MTD, however, they have declined 13.6%, on... 
Via Talk Markets
Topics Artificial Intelligence
Cathie Wood Mops Up $8.1M Worth Of Zoom Stock After Q2 Earnings Beat, Sells Nvidia Shares In Excess Of $1M
 
Via Benzinga
Topics Earnings
Cathie Wood Sells Shopify Shares Worth $9.2M — Ark Goes Shopping This Dutch Payment Company's Stock Instead
 
Via Benzinga
Want to Get Rich? 3 Game-Changing Biotech Stocks to Buy Right Now
Biotech stocks may offer some of the most explosive opportunities on the market. Here are three with major catalysts nearing. 
Via InvestorPlace
3 Green Flags for Biotech Stocks in 2023 and Beyond
The industry is changing rapidly, and for the better. 
Via The Motley Fool
Cathie Wood's Ark Invest Continues To Sell Shopify Shares Amid Q2 Ripples
 
Via Benzinga
Cathie Wood's Ark Invest Buys $16M Worth Of Shares Of Flying Taxi Company Archer Aviation — Sells Shopify Stock Worth Millions
 
Via Benzinga
These 9 AI Stocks Are Up 95%, On Average, Since End Of April
Nine artificial intelligence and AI-related stocks, with market caps in excess of $2B, have advanced by +60% since the bubble began to develop at the end of April into early May, with an average... 
Via Talk Markets
Topics Artificial Intelligence
Every AI Stock Cathie Wood Owns, Ranked From Best to Worst
You can find some great AI investment opportunities by looking at the stocks in Wood's Ark Invest portfolio. 
Via The Motley Fool
Topics Artificial Intelligence
3 Things About Recursion Pharmaceuticals That Smart Investors Know
Until it can get some recurring revenue going, it'll be a risky stock to buy. 
Via The Motley Fool
3 AI Stocks You’ll Regret Not Buying Soon
AI will have a big impact on biotech, which could help with drug discovery and create opportunities for these top AI stocks to invest in. 
Via InvestorPlace
Recursion Provides Business Updates and Reports Second Quarter 2023 Financial Results
From Recursion Pharmaceuticals
Via GlobeNewswire
Recursion Bridges the Protein and Chemical Space with Massive Protein-Ligand Interaction Predictions Spanning 36 Billion Compounds
Recursion has predicted the protein target(s) for approximately 36 billion chemical compounds in the Enamine REAL Space, reported to be the world’s largest searchable chemical library. These advances... 
From Recursion Pharmaceuticals
Via GlobeNewswire
Cathie Wood Buys Shares Of Pacific Biosciences, Reduces Exposure To DraftKings And Genius Sports
 
Via Benzinga
2 Healthcare AI Stocks That Could Go Parabolic
Shares of Recursion Pharmaceuticals and GE Healthcare are both up sharply so far this year. 
Via The Motley Fool
Recursion to Participate in Upcoming Investor Conference
From Recursion Pharmaceuticals
Via GlobeNewswire
Here are 3 AI Drug Discovery Stocks to Put on Your Watchlist
Artificial intelligence (AI) has hit the mainstream with fervor. Specifically, generative AI has gone viral with the explosion in ChatGPT users. 
Via MarketBeat
Topics Artificial Intelligence
These 10 AI Stocks Are Up An Average Of 99% In Last 3 Months
Ten artificial intelligence and AI-related (AI&R) stocks, with market capitalizations of +$1.5B, have advanced by 70% or more (average of 99%!) since the bubble began to develop at the end of April.... 
Via Talk Markets
10 Health Care Stocks With Whale Alerts In Today's Session
 
Via Benzinga
< Previous 1 2
...
14 15 16 17 18 19 20 21 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.